Erschienen in:
30.03.2022 | ASO Author Reflections
ASO Author Reflections: Is There Still a Role for Intraperitoneal Oxaliplatin for Colorectal Peritoneal Metastases?
verfasst von:
Abdelkader Taibi, MD, PhD, Martin Hübner, MD, PhD, Clarisse Eveno, MD, PhD, Frederic Dumont, MD, PhD, Olivier Glehen, MD, PhD, Olivia Sgarbura, MD, PhD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 8/2022
Einloggen, um Zugang zu erhalten
Excerpt
Since the development of oxaliplatin (Ox) as a potent intravenous (IV) cytotoxic drug for metastatic colorectal cancer in the late 1990s, there were high hopes for its efficacy in the clinical setting of peritoneal metastases (PM). Its benefit was mostly proved in combination with IV fluorouracil (5-FU).
1 Oxaliplatin was rapidly adopted as an intraperitoneal (IP) drug, as the molecule fulfilled at that time all conditions to be an ideal antineoplastic agent for IP therapy, including documented activity against the malignant disease to be treated. During the same period, hyperthermic intraperitoneal chemotherapy (HIPEC) gained popularity for PM of colorectal origin. Several studies suggested increased local absorption of IP oxaliplatin when combined with 5-FU systemically. Thus, high-dose oxaliplatin (Ox) associated with intravenous 5-FU quickly became the regimen of choice after cytoreductive surgery (CRS).
2 …
